Shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) shot up 3.1% on Monday . The company traded as high as $101.80 and last traded at $101.02, with a volume of 779,024 shares. The stock had previously closed at $98.01.

A number of brokerages have weighed in on VRTX. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Saturday, June 18th. Vetr cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating and set a $94.38 price target for the company. in a research report on Tuesday, May 31st. Maxim Group reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, April 28th. Barclays PLC reduced their price target on Vertex Pharmaceuticals from $135.00 to $110.00 and set an “overweight” rating for the company in a research report on Thursday, April 28th. Finally, Royal Bank Of Canada reduced their price target on Vertex Pharmaceuticals from $135.00 to $115.00 and set an “outperform” rating for the company in a research report on Thursday, April 28th. Nine investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. Vertex Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $120.43.

The stock has a 50-day moving average of $95.72 and a 200-day moving average of $88.30. The stock’s market cap is $25.24 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Wednesday, July 27th. The pharmaceutical company reported $0.24 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.21 by $0.03. During the same quarter last year, the business earned ($0.54) earnings per share. The company had revenue of $431.61 million for the quarter, compared to analyst estimates of $428.08 million. The company’s revenue was up 159.9% on a year-over-year basis. On average, analysts expect that Vertex Pharmaceuticals Inc. will post $1.04 earnings per share for the current year.

In other Vertex Pharmaceuticals news, Director Joshua S. Boger sold 900 shares of the firm’s stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $100.19, for a total transaction of $90,171.00. Following the completion of the sale, the director now directly owns 268,225 shares in the company, valued at $26,873,462.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Joshua S. Boger sold 5,130 shares of the firm’s stock in a transaction that occurred on Wednesday, June 1st. The stock was sold at an average price of $93.65, for a total transaction of $480,424.50. Following the sale, the director now owns 268,225 shares of the company’s stock, valued at $25,119,271.25. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have made changes to their positions in the company. Calvert Investment Management Inc. boosted its position in shares of Vertex Pharmaceuticals by 30.0% in the fourth quarter. Calvert Investment Management Inc. now owns 11,843 shares of the pharmaceutical company’s stock valued at $1,490,000 after buying an additional 2,734 shares in the last quarter. KBC Group NV boosted its position in shares of Vertex Pharmaceuticals by 53.0% in the fourth quarter. KBC Group NV now owns 42,623 shares of the pharmaceutical company’s stock valued at $5,363,000 after buying an additional 14,759 shares in the last quarter. Nicholas Co. Inc. WI boosted its position in shares of Vertex Pharmaceuticals by 4.8% in the fourth quarter. Nicholas Co. Inc. WI now owns 44,035 shares of the pharmaceutical company’s stock valued at $5,540,000 after buying an additional 2,000 shares in the last quarter. American International Group Inc. boosted its position in shares of Vertex Pharmaceuticals by 2.0% in the fourth quarter. American International Group Inc. now owns 110,088 shares of the pharmaceutical company’s stock valued at $13,852,000 after buying an additional 2,175 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Vertex Pharmaceuticals by 5.7% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 625,112 shares of the pharmaceutical company’s stock valued at $78,658,000 after buying an additional 33,936 shares in the last quarter.

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.